DZ: Writing review & editing, Funding acquisition
Fogacci F, Di Micoli V, Sabouret P, Giovannini M, Cicero AFG
The process of choosing weight loss injection therapy is rarely about selecting the strongest medication
I understand Kaiser removed GLP-1 weight loss medications (like Wegovy/Wegovy) from base coverage in 2025, but some employers opted to add this benefit
By testing variants in GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313plus 46 additional peptides across 14 pathwaysthe test identifies whether you'll respond best to semaglutide, tirzepatide, or specialized formulations
There are no known direct drug interactions between semaglutide and commonly prescribed antibiotics that would make their concurrent use unsafe